Having recommended NHS use of sunitinib for renal cancer, the appraisal committee of the National Institute of Health and Clinical Excellence (NICE) issued separate draft guidance for consultation, recommending against […]
Tag: end of life drugs
James Raftery: End of life drugs—what premium? Pt 1
The National Institute for Health and Clinical Excellence (NICE), the UK drugs watchdog, is currently appraising the use of four drugs—bevacizumab, sorafenib, sunitinib, and temsirolimus—for the treatment of advanced or […]